Results 61 to 70 of about 64,446 (303)

Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications [PDF]

open access: yes, 2018
© The Author(s) 2018The stability of an arterial thrombus, determined by its structure and ability to resist endogenous fibrinolysis, is a major determinant of the extent of infarction that results from coronary or cerebrovascular thrombosis.
A Gast   +66 more
core   +2 more sources

Antibacterial Applications of Black and Violet Phosphorus‐Based Biomaterials

open access: yesAdvanced NanoBiomed Research, EarlyView.
Black and violet phosphorus‐based biomaterials exhibit broad‐spectrum antibacterial efficacy in various infections, including bone, skin, ocular, dental, lung, and sepsis cases. Their antibacterial mechanisms include physical disruption, light‐driven effects, targeted drug delivery, and enhanced composite strategies.
Zhuo Dai   +8 more
wiley   +1 more source

Management of Antithrombotic Agents in Oral Surgery Maria Martinez and Dimitrios A. Tsakiris *

open access: yesDentistry Journal, 2015
Systemic anticoagulation with intravenous or oral anticoagulants and antiplatelet agents is an efficient treatment against thromboembolic or cardiovascular disease.
Maria Martinez, Dimitrios A. Tsakiris
doaj   +1 more source

Prescribing of medication to prevent glucocorticoid harms in patients with Polymyalgia Rheumatica: a cross‐sectional study and two emulated target trials in the Clinical Practice Research Datalink Aurum

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives Polymyalgia rheumatica (PMR) is a common indication for long‐term glucocorticoid (GC) treatment. Bone‐ and gastro‐protective medications are recommended for those at high‐risk of adverse events from GCs but no trials have evaluated their effectiveness in PMR.
Helen Twohig   +5 more
wiley   +1 more source

Effect of direct oral anticoagulant therapy on pulmonary artery clot dissolution in intermediate high-risk pulmonary thromboembolism

open access: yesThrombosis Journal
Background Direct oral anticoagulants are the established drugs for treating pulmonary thromboembolism. The advantage of direct oral anticoagulants over conventional therapy for clot lysis and right ventricular unloading in the acute phase remains ...
Hiroya Hayashi   +10 more
doaj   +1 more source

Anticoagulant Therapy in “Fragile” Elderly Patients: Current State of the Problem

open access: yesРациональная фармакотерапия в кардиологии, 2019
The review focuses on the use of oral anticoagulants in fragile elderly patients. The issues of prevalence and diagnosis of senile asthenia syndrome or “fragility”, as well as its effects on the risks of thrombosis, bleeding and death, are discussed. The
N. M. Vorobyeva, O. N. Tkacheva
doaj   +1 more source

Direct oral anticoagulants in cancer-associated venous thromboembolism

open access: yesVascular Investigation and Therapy, 2020
This is a narrative review of the relevant literature on the epidemiology, pathogenesis, and treatment of venous thromboembolism (VTE) in cancer patients.
Kirill Lobastov   +2 more
doaj   +1 more source

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms [PDF]

open access: yes, 2018
We analyzed 597 patients with myeloproliferative neoplasms (MPN) who presented transient ischemic attacks (TIA, n = 270) or ischemic stroke (IS, n = 327). Treatment included aspirin, oral anticoagulants, and cytoreductive drugs.
Arellano-Rodrigo, Eduardo   +41 more
core   +5 more sources

Human vs. artificial intelligence: Physicians outperform ChatGPT in real‐world pharmacotherapy counselling

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims To assess the utility of the artificial intelligence (AI) chatbot ChatGPT (openly available version 3.5) in responding to real‐world pharmacotherapeutic queries from healthcare professionals. Methods Three independent and blinded evaluators with different levels of medical expertise and professional experience (beginner, advanced, and expert ...
Benjamin Krichevsky   +9 more
wiley   +1 more source

Allosteric Inhibition of Factor XIIIa. Non-Saccharide Glycosaminoglycan Mimetics, but Not Glycosaminoglycans, Exhibit Promising Inhibition Profile [PDF]

open access: yes, 2016
Factor XIIIa (FXIIIa) is a transglutaminase that catalyzes the last step in the coagulation process. Orthostery is the only approach that has been exploited to design FXIIIa inhibitors.
Afosa, Daniel K.   +4 more
core   +4 more sources

Home - About - Disclaimer - Privacy